Oramed Pharmaceuticals (ORMP) Interest & Investment Income (2012 - 2026)

Oramed Pharmaceuticals (ORMP) has 6 years of Interest & Investment Income data on file, last reported at $276000.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 57.34% year-over-year to $276000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 2.42% YoY) and the FY2025 annual result came in at $2.4 million, down 52.38% from the prior year.
• Interest & Investment Income declined to $276000.0 in Q1 2026, from $647000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $2.5 million in Q2 2023 to a low of $158000.0 in Q4 2022.
• A 4-year average of $864285.7 and a median of $544000.0 in 2022 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2023 — Interest & Investment Income soared 608.0% — and 2026, when it plunged 57.34%.
• Tracing ORMP's Interest & Investment Income over 4 years: stood at $158000.0 in 2022, then jumped by 1468.35% to $2.5 million in 2023, then slumped by 73.89% to $647000.0 in 2025, then tumbled by 57.34% to $276000.0 in 2026.
• The last three Interest & Investment Income figures came in at $276000.0 (Q1 2026), $647000.0 (Q1 2025), and $2.5 million (Q2 2023), per Business Quant data.